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Anxiety and depression are highly prevalent in individuals 
with heart disease.1–3 Anxiety disorders are the most common 
mental illnesses in the United States with 31% estimated life-
time prevalence.4 An estimated 6.7% of adults experienced an 
episode of depression, a potentially debilitating mental ill-
ness, in a typical 12-month period.5 Among individuals with 
coronary heart disease, 36% were found to have anxiety dis-
order.2 The 12-month prevalence of major depression was 
estimated at 9.3% for patients with coronary heart disease.6
Platelet aggregation inhibitors (PAIs) are a cornerstone of 
treatment for atherosclerotic cardiovascular disease (ASCVD) 
including secondary prevention and risk reduction for coro-
nary artery disease (CAD),7 peripheral artery disease (PAD),8 
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Abstract
Objective: Medications commonly used to treat heart disease, anxiety, and depression can interact resulting in an increased 
risk of bleeding, warranting a cautious approach in medical decision making. This retrospective, descriptive study examined 
the prevalence and the factors associated with the use of both selective-serotonin reuptake inhibitor and platelet aggregation 
inhibitor among individuals with co-occurring atherosclerotic cardiovascular disease and anxiety or depression.
Methods: Respondents aged 22 years and older, alive throughout the study period, and diagnosed with co-occurring 
atherosclerotic cardiovascular disease and anxiety or depression (n = 1507) in years 2007 through 2013 of the Medical 
Expenditures Panel Survey were included. The use of treatment was grouped as follows: selective-serotonin reuptake 
inhibitor and platelet aggregation inhibitor, selective-serotonin reuptake inhibitor or platelet aggregation inhibitor, and 
neither selective-serotonin reuptake inhibitor nor platelet aggregation inhibitor.
Results: Overall, 16.5% used both selective-serotonin reuptake inhibitor and platelet aggregation inhibitor, 61.2% used 
selective-serotonin reuptake inhibitor or platelet aggregation inhibitor, and 22.3% used neither selective-serotonin reuptake 
inhibitor nor platelet aggregation inhibitor. Respondents aged over 65 years (adjusted odds ratio = 1.93 (95% confidence 
interval = 1.08–3.45)) and having a diagnosis of diabetes (adjusted odds ratio = 1.63 (95% confidence interval = 1.15–2.31)) 
and hypertension (adjusted odds ratio = 1.84 (95% confidence interval = 1.04–3.27)) were more likely to be prescribed the 
combination.
Conclusion: The drug interaction was prevalent in patients who are already at higher risk of health disparities and worse 
outcomes thus requiring vigilant evaluation.
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and acute coronary syndromes (ACS) with percutaneous coro-
nary intervention (PCI)9 or coronary artery bypass graft 
(CABG).10 Adverse effects of PAIs can include major or minor 
bleeding, gastrointestinal bleeding, hematoma, and less fre-
quently, hemorrhagic stroke.11,12 PAI are also used for second-
ary prevention and risk reduction for CADs.9,13
Selective-serotonin reuptake inhibitors (SSRIs) are first-
line therapy for anxiety disorders including generalized 
anxiety disorder, post-traumatic stress disorder,14 obsessive-
compulsive disorder,15 and panic disorders.16 SSRIs are also 
potential first-line therapies for mild, moderate, or severe 
major depressive disorder (MDD). The evidence for depres-
sion treatment affecting cardiovascular outcomes is the 
Enhancing Recovery in Coronary Heart Disease (ENRICHD) 
study which had a post hoc finding that a subset of patients 
receiving an SSRI had better outcomes.17
Among patients with ASCVD and depression or anxiety, 
some patients may be treated with an SSRI and a PAI. When 
these medications are given in combination, platelet aggrega-
tion may be impaired and the risk of bleeding events can be 
increased.18,19 These events include stomach bleeding, bruis-
ing, nose bleeding, and other serious internal or external 
bleeding. This interaction has been assessed in non-US popu-
lations to show that SSRIs increased the risk of lower gastro-
intestinal bleeds (distal to the ligament of Treitz),20 and the 
combined use of a PAI with an SSRI is associated with an 
increased risk of bleeding.21 Therefore, it is important to moni-
tor individuals with this medication combination. However, 
the extent to which SSRI/PAI combination occurs in real-
world practice settings is not known. Furthermore, no study 
has assessed subgroup differences in SSRI/PAI combination 
use among adults with co-occurring ASCVD and anxiety or 
depression in the United States. Therefore, the primary objec-
tive of this study was to estimate the prevalence of SSRI/PAI 
combination among adults with co-occurring ASCVD and 
anxiety or depression. The secondary objective was to analyze 
subgroup differences in individuals using SSRI/PAI combina-
tion compared to those who received either SSRI or PAI.
Conceptual framework
Factors associated with SSRI/PAI use categories were guided 
by the Andersen expanded behavioral model for use of health 
services.22 This model states that healthcare treatments are 
affected by (1) an individual’s predisposing factors, (2) the 
factors which enable individuals to receive services, (3) the 
individual’s level of need for the healthcare services, (4) per-
sonal health practices, and (5) the external healthcare envi-
ronment. In this study, predisposing factors consisted of 
gender, race, and age; enabling factors included education, 
poverty status as a percentage of the federal poverty line 
(FPL), health insurance coverage, and prescription drug cov-
erage; and need factors were perceived physical and mental 
health of the individuals as well as presence of diabetes or 
hypertension. Personal health practices included obesity 
measured with body mass index (BMI), exercise frequency, 
and smoking status. The external healthcare environment 
was represented by geographic region.
Methods
Study design
This is a retrospective, cross-sectional study designed to ana-
lyze patterns of SSRI/PAI combination use among adults 
with co-occurring ASCVD and anxiety or depression. In this 
study, ASCVD included ACS, history of myocardial infarc-
tion, angina (stable or unstable), arterial revascularization, or 
peripheral arterial disease related to atherosclerosis.23
Data source
This study used the Medical Expenditures Panel Survey 
(MEPS), a publicly available, nationally representative (of 
the civilian, non-institutionalized population) set of sur-
veys.24 MEPS data are released in full-year consolidated 
household files, medical conditions, prescription drug 
events, and others. Full-year consolidated household files 
contain individual-level data on demographics, healthcare 
expenditures, healthcare use, sources of payments, and 
health insurance coverage. The Medical Conditions files 
contain information on conditions taken from respondents 
which were coded to International Classification of Disease, 
9th Edition, Clinical Modification (ICD-9-CM) codes by 
professional coders then were converted by Agency for 
Healthcare Research and Quality (AHRQ) to clinical clas-
sification codes. The information in the Prescribed 
Medicines files are at the event-level, and each record is a 
unique prescribed medicine including national drug code 
(NDC), medicine name, and any conditions reported with 
the prescription processing. NDCs were mapped to a thera-
peutic class based on Multum Lexicon therapeutic classifi-
cation system and were made available to the researchers in 
the MEPS.25
Analytical sample
Individuals aged 22 years or older, alive during the calendar 
year, had co-occurring ASCVD and anxiety or depression 
were included in the sample for the analysis. ASCVD was 
identified using three-digit ICD-9-CM codes from the medi-
cal conditions files of the MEPS. We restricted the analysis 
to those with ASCVD because PAIs are used in these condi-
tions. ASCVD were identified using the following ICD-
9-CM codes as has been done in the previous research:26–29 
410.x, 411.x, 412.x, 413.x, 414.x, 429.x, 440.x, and 443.x. 
Anxiety was defined with clinical classification code 651 
and mood disorders were determined with clinical classifica-
tion code 657. The analytical sample consisted of 1,507 
unique individuals (Figure 1).
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Measures
Dependent variable
SSRIs and PAIs were identified using the event-level data 
from the prescription drug files and were aggregated at the 
person-level. Multum-lexicon therapeutic class code of 208 
represented SSRIs. Medications in this class included cital-
opram, escitalopram, fluoxetine, fluvoxamine, paroxetine, 
and sertraline. PAIs were identified with code 211. 
Medications in this category include prescription, oral 
agents: clopidogrel, cilostazol, prasugrel, ticagrelor, and 
ticlopidine. SSRI and PAI use was combined to yield the 
following three categories: (1) SSRI and PAI, (2) SSRI or 
PAI, and (3) no SSRI and no PAI.
Independent variables
The independent variables were as follows: gender (male 
and female); race (White, African American, and other 
minorities); age in years (22–49, 50–64, and ⩾65); educa-
tion (less than high school, high school, and more than high 
school); poverty status (poor, near poor, middle income, 
and high income); insurance coverage (private, public, and 
uninsured); prescription drug coverage (yes, and no); per-
ceived physical health (excellent/very good, good, and fair/
poor); perceived mental health (excellent/very good, good, 
and fair/poor); diagnosis of diabetes (diabetes and no dia-
betes); diagnosis of hypertension (hypertension and no 
hypertension); obesity (underweight/normal, overweight, 
and obese); exercise frequency (at least three times per 
week and less than three times per week); smoking status 
(current smoker, former and non-smoker); and region 
(northeast, mid-west, south, and west). There were 19 indi-
viduals who had missing data on obesity and 89 individuals 
had missing data on smoking status. For these individuals, 
we created missing indicators and these were included in 
the regression analyses.
Whites and African Americans were identified in the race 
variable and Hispanics were identified in the ethnicity vari-
able. These were combined to Whites, African Americans, 
Hispanic, and other minorities. However, due to low cell 
counts in other minorities, Hispanic and other minorities 
were combined. Region categories were based on the census 
region at the beginning of the survey period.
Statistical analysis
Unadjusted group differences in SSRI and PAI use categories 
were tested with chi-square statistics. As the SSRI and PAI use 
consisted of three treatment categories, multinomial logistic 
regression was used to analyze patterns of SSRI and PAI use. 
The reference group for the dependent variable was “SSRI or 
PAI” use. The reference group was chosen because that is the 
condition where the SSRI and PAI interaction would not occur, 
and the group receiving neither therapy is being potentially 
undertreated. The independent variables with corresponding 
Figure 1. Final study sample: inclusion and exclusion criteria of the Medical Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
MEPS: Medical Expenditures Panel Survey; ASCVD: atherosclerotic cardiovascular disease; PAD: peripheral arterial disease; GI: gastrointestinal; SSRI: 
selective-serotonin reuptake inhibitors; PAI: platelet aggregation inhibitors.
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Table 1. Characteristics of adults with co-occurring 
atherosclerotic cardiovascular disease and depression or anxiety: 
Medical Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
All N = 1507 Wt.%
Predisposing factors
 Gender
  Female 907 59.2
  Male 600 40.8
 Race/ethnicity
  White 957 80.3
  African American 240 8.0
  Others 310 11.7
 Age (years)
  22–49 223 13.9
  50–64 586 37.0
  ⩾65 698 49.2
Enabling factors
 Education level
  Less than high school 473 24.4
  High school graduate 521 36.9
  Greater than high school 506 38.7
 Poverty status
  Poor (<100% of FPL) 433 20.9
  Near poor (100%–199% FPL) 427 27.3
  Middle income (200%–399% FPL) 380 27.5
  High income (400% or greater FPL) 267 24.2
 Insurance coverage
  Private 639 51.7
  Public 778 44.0
  Uninsured 90 4.4
 Prescription drug insurance
  Prescription coverage 795 57.9
  No prescription coverage 712 42.1
Need factors
 Perceived physical health
  Excellent or very good 206 16.3
  Good 404 29.8
  Fair or poor 897 53.9
 Perceived mental health
  Excellent or very good 384 29.7
  Good 552 37.4
  Fair poor 571 33.0
 Diabetes
  Diabetes 623 37.6
  No diabetes 883 62.4
 Hypertension
  Hypertension 1262 82.6
  No hypertension 245 17.4
Personal health practices
 Body mass index categories
  Under weight or normal 326 24.4
  Overweight 474 30.8
  Obese 688 43.8
 Exercise frequency
  Three or more times per week 409 28.6
  Less than three times per week 1090 71.0
All N = 1507 Wt.%
 Smoking status+
  Current smoker 360 24.0
  Former or non-smoker 1058 70.1
External healthcare environment
 Region
  Northeast 250 17.7
  Midwest 341 24.1
  South 627 39.7
  West 289 18.4
FPL: Federal Poverty Line; Wt.: weighted.
Based on adults aged 22 years and older with atherosclerotic cardiovascu-
lar disease and either depression or anxiety and without gastrointestinal 
bleeding disorders during 2007, 2009, 2011, and 2013.
Table 1. (Continued)
reference groups are shown in Table 3. For each of the inde-
pendent variables, adjusted odds ratios (AORs), 95% confi-
dence intervals (CIs), and significance levels from the 
multinomial regression are reported. All analyses were con-
ducted considering the complex survey design of MEPS and 
using Statistical Analysis Software (SAS®) version 9.4.
We also conducted secondary analyses in which we 
included all patients on antidepressants that were not SSRIs 
and a PAI as a separate group. It was analyzed using a multi-
nomial logistic regression, so that SSRI/PAI could be com-
pared to non-SSRI antidepressants plus PAI. There were no 
significant differences between these groups; therefore, we 
do not present these results in this article.
Results
Sample description
Table 1 presents the weighted percent of the characteristics 
of the study sample that included individuals with co-occur-
ring ASCVD and anxiety or depression. The majority of the 
sample included female (59.2%), Whites (80.3%), and high 
school graduates (75.6%). Nearly 50% were aged 65 years 
or older. Chronic conditions such as obesity (43.8%), diabe-
tes (37.6%), and hypertension (82.6%) were also prevalent. 
Diabetes was diagnosed in our sample more frequently than 
the national average of 9.3%.30 An overwhelming majority 
(82.6%) had hypertension, and the percentage of current 
smokers (24.0%) was higher than the national average of 
19% in 201131 and 16.8% in 2014.32
Description of the sample by SSRI/PAI treatment 
categories
Overall, 16.5% used SSRI/PAI combination, 61.2% used 
either SSRI or PAI, and 22.3% used neither SSRI nor PAI. 
There were statistically significant differences in SSRI/PAI 
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treatment categories by race/ethnicity (p < 0.001), age 
(p = 0.009), insurance coverage (p = 0.014), diabetes diagno-
sis (p < 0.001), and hypertension diagnosis (p = 0.001). Full 
group differences can be seen in Table 2. A higher percentage 
of adults with diabetes (21.6%) used SSRI/PAI combination 
compared to adults without diabetes (13.4%).
Multinomial logistic regression on SSRI/PAI 
treatment categories
AORs, 95% CIs, and significance levels from multinomial 
logistic regression on SSRI and PAI use categories for each 
of the independent variable are presented in Table 3. SSRI 
and PAI use was more likely among older adults 
(age > 65 years) (AOR = 1.93 (95% CI = 1.08–3.45)), those 
with diabetes (AOR = 1.63 (95% CI = 1.15–2.31)), and those 
with hypertension (AOR = 1.84 (95% CI = 1.04–3.27)) than 
among younger adults, those without diabetes, and those 
without hypertension.
Discussion
This study sets out to examine the combined use of SSRI and 
PAI among adults with co-occurring ASCVD and anxiety or 
depression. According to the practice guidelines, SSRIs can 
be a reasonable first option for treating anxiety and depres-
sion. PAIs are considered a cornerstone of pharmacotherapy 
for many types of ASCVD. Although the mechanism is not 
clear, many studies have shown that combined use of SSRI 
and PAI is associated with an increased risk of bleeding 
events.21,33 Therefore, we considered the combined SSRI and 
PAI use as treatment to be used with caution and one which 
requires closer monitoring and follow-up to reduce the risk 
of adverse consequences.
Our study found that one in six adults aged 22 years and 
older with co-occurring ASCVD and anxiety or depression 
used SSRI and PAI in combination. Given the bleeding risk 
reported by previous studies,20,21 our findings suggest that 
alternatives to SSRIs need to be considered. However, all anti-
depressants are not equal in their potential impact on cardio-
vascular adverse events. Selective serotonin reuptake inhibitors 
are generally considered safer than tricyclic antidepressants.34 
Psychotherapy is another alternative that has been effectively 
used to treat depression after an acute myocardial infarction,35 
but psychotherapy is not widely used because of its limited 
availability and affordability. For example, only 2.8% of a sam-
ple from a previous MEPS study used psychotherapy in 2007 
for treatment of depression.36 Lack of available mental health 
services was identified as a barrier to psychotherapy use by 
21.6% of a surveyed sample of patients.37 In a 2009 survey of 
mental health services use, 46% indicated that cost was the rea-
son for not receiving mental health services.38 Therefore, the 
physicians may need to individualize the treatment based on 
the benefits and risks of SSRI/PAI combination use and the 
patient’s financial situation.
The use of the SSRI/PAI combination was more likely 
among older adults (>65 years) in both the unadjusted and 
adjusted analyses. Increased age has a marked effect on 
platelet function and mental health conditions including 
depression and anxiety. Platelet function decreases with age 
thus leading to an increased risk of thrombotic diseases.39 
Additionally, elderly adults tend to be more reluctant to 
report symptoms of depression thus present with more severe 
disease requiring pharmacological intervention.40 Choosing 
a treatment for ASCVD and depression or anxiety in elderly 
patients need to be done with caution and take into account 
their higher risk of thrombotic events.
In our study sample of adults with ASCVD and co-
occurring anxiety of depression, there was a high preva-
lence of diabetes and/or hypertension and these individuals 
were more likely to use SSRI and PAI in combination. 
Patients with multiple chronic conditions or multimorbid-
ity have complex medical needs41 in which prescribed 
medications which could interact and this also affects 
quality of life, work productivity, employability, and mor-
tality.42 It is worth noting that in our study, a special type 
of multimorbidity, the presence of both chronic physical 
and mental health conditions, was also highly prevelant.41 
This combination is important because mental health con-
ditions such as depression can produce the greatest burden 
compared to multimorbidity in chronic conditions without 
depression.43 In the United States, the strategic framework 
for improving health outcomes and quality of life among 
those with multimorbidity calls for special attention to the 
presence of both chronic physical and mental health condi-
tions.44 Therefore, our findings highlight the need for a 
team-based approach with physicians, mental health spe-
cialists, pharmacists, and case managers who can provide 
support for prescription monitoring, patient awareness, 
and education.
The significant association with diabetes diagnosis and 
combined use of SSRI/PAI is important for two reasons: (1) 
patients with diabetes already have increased risk for bleeding 
relating to peptic ulceration45 and (2) low potency PAI (e.g. 
aspirin and clopidogrel) may be less effective in these patients 
thus requiring more potent agents (e.g. prasugrel and ticagre-
lor).46 Patients with multimorbidity (at minimum ASCVD, 
diabetes, and anxiety or depression) are now at a potentially 
greater risk for adverse effects associated with the medication 
combination and may not be able to identify which medica-
tions are the offending agents. The prescriber now needs to 
balance the harms and benefits of adding more potent PAIs to 
the regimen for patients with diabetes and ASCVD. Another 
chronic disease, hypertension, did have a significant associa-
tion with treatment choice and was highly prevalent. This 
association could also result from heart disease having treat-
ments that overlap with hypertension treatment (e.g. beta-
blockers or angiotensin-converting-enzyme inhibitors).
Strengths of this study include that it is based on physio-
logic and conceptual frameworks that attempted to address an 
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Table 2. SSRI and PAI use among adults with co-occurring atherosclerotic cardiovascular disease and depression or anxiety: Medical 
Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
SSRI and PAI SSRI or PAI No SSRI and no PAI
 N Wt.% N Wt.% N Wt.% Sig.
All 254 16.5 894 61.2 359 22.3 –
Predisposing factors
 Gender
  Female 150 16.1 539 61.8 218 22.2  
  Men 104 17.0 355 60.4 141 22.6  
 Race/ethnicity ***
  White 154 15.7 596 63.1 207 21.3  
  African American 32 13.8 136 53.3 72 32.9  
  Others 68 23.8 162 53.8 80 22.4  
 Age (years) **
  22–49 21 8.9 133 61.7 69 29.4  
  50–64 99 16.6 365 64.5 122 18.9  
  65 134 18.5 396 58.6 168 23.0  
Enabling factors
 Education level
  Less than high school 95 19.2 265 57.3 113 23.5  
  High school graduate 90 16.8 308 61.7 123 21.5  
  Greater than high school 67 14.3 317 63.1 122 22.6  
 Poverty level
  Poor (<100% of FPL) 76 16.9 248 58.8 109 24.4  
  Near poor (100%–199% FPL) 68 16.4 250 59.8 109 23.8  
  Middle income (200%–399% FPL) 63 14.8 225 61.5 92 23.7  
  High income (400% or greater FPL) 47 18.0 171 64.6 49 17.4  
 Insurance coverage *
  Private 103 15.5 391 63.3 145 21.2  
  Public 141 18.0 463 60.0 174 22.0  
  Uninsured 10 12.0 40 48.6 40 39.4  
 Prescription drug insurance
  Prescription coverage 134 15.8 495 63.7 166 20.5  
  No prescription coverage 120 17.3 399 57.7 193 24.9  
Need factors
 Perceived physical health
  Excellent or very good 28 15.3 112 54.7 66 30.0  
  Good 69 16.1 246 63.9 89 19.9  
  Fair or poor 157 17.0 536 61.7 204 21.4  
 Perceived mental health
  Excellent or very good 58 16.3 227 59.0 99 24.6  
  Good 97 16.4 313 61.1 142 22.5  
  Fair poor 99 16.6 354 63.3 118 20.1  
 Diabetes ***
  Diabetes 134 21.6 380 61.7 109 16.7  
  No diabetes 120 13.4 514 61.0 249 25.6  
 Hypertension **
  Hypertension 229 18.0 752 61.1 281 20.8  
  No hypertension 25 8.9 142 61.6 78 29.5  
Personal health practices
 Body mass index categories
  Underweight or normal 53 15.4 185 60.0 88 24.6  
  Overweight 87 18.8 269 57.7 118 23.5  
  Obese 110 15.3 429 64.1 149 20.6  
Thornton et al. 7
SSRI and PAI SSRI or PAI No SSRI and no PAI
 N Wt.% N Wt.% N Wt.% Sig.
 Exercise frequency
  Three times per week or more 72 17.6 238 61.0 99 21.4  
  Less than three times per week 179 15.8 652 61.4 259 22.8  
 Smoking status+
  Current smoker 60 17.4 233 64.8 67 17.8  
  Former or non-smoker 180 16.3 614 60.1 264 23.5  
External healthcare environment
 Region
  Northeast 56 20.0 144 62.2 50 17.9  
  Midwest 53 16.8 214 62.4 74 20.8  
  South 92 14.1 373 62.1 162 23.7  
  West 53 17.7 163 56.7 73 25.6  
FPL: Federal Poverty Line; PAI: platelet aggregation inhibitor; Sig.: significance; SSRI: selective-serotonin reuptake inhibitor; Wt.: weighted.
Based on adults aged 22 years and older with atherosclerotic cardiovascular disease and either depression or anxiety and without gastrointestinal bleed-
ing disorders during 2007, 2009, 2011, and 2013. The percentage columns represent the weight row percentages for each group. Asterisks represent 
significant group differences SSRI PAI use based on chi-square tests. Missing categories smoking and body mass index categories not presented.
***p < 0.001, **0.001 ⩽ p < 0.01; *0.01 ⩽ p < 0.05.
(Continued)
Table 2. (Continued)
Table 3. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) from multinomial logistic on SSRI PAI use with co-occurring 
atherosclerotic cardiovascular disease and depression or anxiety: Medical Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
SSRI and PAI Sig. No SSRI and no PAI Sig.
 AOR 95% CI AOR 95% CI
Predisposing factors
 Gender
  Male  
  Female 0.97 (0.69–1.36) 0.83 (0.59–1.17)  
 Race/ethnicity
  White  
  African American 0.95 (0.62–1.44) 1.88 (1.27–2.79) **
  Others 1.57 (0.98–2.53) 1.17 (0.75–1.83)  
 Age (years)
  22–49  
  50–64 1.65 (0.90–3.04) 0.66 (0.42–1.05)  
  ⩾65 1.93 (1.08–3.45) * 0.82 (0.54–1.25)  
Enabling factors
 Education level
  Less than high school 1.38 (0.91–2.11) 1.11 (0.75–1.65)  
  High school 1.21 (0.79–1.84) 0.91 (0.63–1.31)  
  Greater than high school  
 Poverty status
  Poor 0.97 (0.55–1.71) 1.54 (0.89–2.67)  
  Near poor 0.84 (0.50–1.42) 1.51 (0.95–2.38)  
  Middle income 0.81 (0.49–1.35) 1.50 (0.95–2.37)  
  High income  
 Insurance coverage
  Uninsured  
  Private 1.00 (0.40–2.52) 0.37 (0.21–0.68) **
  Public 1.07 (0.43–2.68) 0.33 (0.19–0.56) ***
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SSRI and PAI Sig. No SSRI and no PAI Sig.
 AOR 95% CI AOR 95% CI
 Prescription drug insurance  
  No drug coverage  
  Drug coverage 0.92 (0.62–1.36) 0.76 (0.53–1.07)  
Need factors
 Perceived physical health
  Excellent and very good  
  Good 0.91 (0.54–1.54) 0.58 (0.35–0.95) *
  Fair/poor 0.97 (0.58–1.63) 0.69 (0.43–1.10)  
 Perceived mental health
  Excellent and very good  
  Good 0.89 (0.54–1.48) 0.97 (0.65–1.44)  
  Fair/poor 0.85 (0.52–1.38) 0.75 (0.48–1.18)  
 Diabetes
  No diabetes  
  Diabetes 1.63 (1.15–2.31) ** 0.66 (0.47–0.92) *
 Hypertension
  No hypertension  
  Hypertension 1.84 (1.04–3.27) * 0.76 (0.54–1.08)  
Personal health practices
 Body mass index categories
  Underweight/normal  
  Overweight 1.15 (0.77–1.72) 0.89 (0.59–1.34)  
  Obese 0.81 (0.54–1.23) 0.80 (0.54–1.18)  
 Exercise frequency
  Three or more times per week  
  No exercise 0.83 (0.56–1.23) 1.22 (0.85–1.75)  
 Smoking status+
  Former or non-smoker  
  Current smoker 1.12 (0.73–1.72) 0.63 (0.44–0.92) *
External healthcare environment
 Region
  Northeast  
  Midwest 0.95 (0.60–1.50) 1.09 (0.63–1.86)  
  South 0.73 (0.45–1.17) 1.23 (0.77–1.99)  
  West 0.99 (0.58–1.67) 1.38 (0.81–2.35)  
FPL: Federal Poverty Line; PAI: platelet aggregation inhibitor; Sig.: significance; SSRI: selective-serotonin reuptake inhibitor; Wt.: weighted.
Based on adults aged 22 years and older with atherosclerotic cardiovascular disease and either depression or anxiety and without gastrointestinal bleed-
ing disorders during 2007, 2009, 2011, and 2013. Asterisks represent significant group differences SSRI PAI compared to the reference group based on 
multinomial logistic regression. Missing categories smoking and body mass index categories not presented.
***p < 0.001, **0.001 < p < 0.01; *0.01 ⩽ p < 0.05.
issue which occurs frequently when treating co-occurring 
ASCVD and anxiety or depression and it was performed in a 
real-world, nationally representative sample of the US popu-
lation. Potential limitations to this study include that the 
Multum Lexicon used to identify PAI does not include over-
the-counter aspirin, a commonly used medication in this 
class, but would include prescription aspirin. Long-term aspi-
rin can be used to inhibit platelet aggregation. Additionally, 
the Multum Lexicon used to identify SSRI is exclusive to that 
class and does not include selective-norepinephrine reuptake 
inhibitor (SNRI) medications. Finally, due to the cross-sec-
tional study design, the timing of the different medications 
and disease states could not be assessed. Future research 
needs to explore the reasons for the combined use of SSRI 
and PAI and its utility in a clinical setting.
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